en · de · es · fr · pt
hplc-notes.peptides4800.com › Blog › Ipamorelin Background And Receptor Selectivity — Practical Notes

Ipamorelin Background And Receptor Selectivity — Practical Notes

By Editorial Desk · published 2025-08-03 · last reviewed 2025-09-07 · Blog

This is a working overview of GHSR-1a, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-09-07 and is reviewed periodically as new material appears.

Ipamorelin Background and Receptor Selectivity

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.

Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.

Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.

Background and Receptor Selectivity

The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.

Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.

Ipamorelin at a glance

PropertyValueNotes
Molecular formulaC38H49N9O5Pentapeptide with amidated C-terminus
Molecular weight711.85 g/molMonoisotopic mass
Primary receptorGHS-R1aGhrelin receptor, Gq/11 coupled
Peptide classSynthetic pentapeptideContains two non-natural residues
Reported selectivityLower cortisol and prolactin effectObserved in animal and early human work

背景与分子特征

在 GHS 家族中,早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放,并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性,对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同,而完整的分子解释仍有待补充。需要区分的是,选择性是研究观察中的相对程度,并非绝对界限。

从用途定位看,ipamorelin 目前主要以研究用肽的身份被讨论,未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用,不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小,因此对其效应强度与一致性的描述应保持谨慎。

Ipamorelin 是一种合成五肽,序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2,分子式 C38H49N9O5,游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素(GHS)家族,作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道,设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。

Related pages on this site

Background and Structural Identity

Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.

The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.

Receptor Selectivity and Secretagogue Signaling

Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.

Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.

Analytical Methods and Storage Stability

Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.

Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.

Supporting material

Beneš—the leader of the Czechoslovak government-in-exile—and František Moravec—head of Czechoslovak military intelligence—organized and coordinated a resistance network. Hácha, Prime Minister Alois Eliáš, and the Czechoslovak resistance acknowledged Beneš's leadership. Active collaboration between London and the Czechoslovak home front was maintained throughout the war years. The most important event of the resistance was Operation Anthropoid, the assassination of Reinhard Heydrich, SS leader Heinrich Himmler's deputy and the then Protector of Bohemia and Moravia. Infuriated, Hitler ordered the arrest and execution of 10,000 randomly selected Czechs. Over 10,000 were arrested, and at least 1,300 were executed. According to one estimate, 5,000 were killed in reprisals. The assassination resulted in one of the most well-known reprisals of the war. The Nazis completely destroyed the villages of Lidice and Ležáky; all men over 16 years from the village were murdered, and the rest of the population was sent to Nazi concentration camps where many women and nearly all the children were killed. The Czechoslovak resistance comprised four main groups:

Bach MK, Brashler JR, Morton DR Jr (1984). "Solubilization and characterization of the leukotriene C4 synthetase of rat basophil leukemia cells: a novel, particulate glutathione S-transferase". Arch. Biochem. Biophys. 230 (2): 455–65. doi:10.1016/0003-9861(84)90426-0. PMID 6324687. Shimizu T (1988). "Enzymes functional in the syntheses of leukotrienes and related compounds". Int. J. Biochem. 20 (7): 661–6. doi:10.1016/0020-711X(88)90160-7. PMID 2846379. Lam BK, Austen KF (2002). "Leukotriene C4 synthase: a pivotal enzyme in cellular biosynthesis of the cysteinyl leukotrienes". Prostaglandins. Other. Lipid. Mediat. 68–69: 511–20. doi:10.1016/S0090-6980(02)00052-7. PMID 12432940. Christmas P, Weber BM, McKee M, Brown D, Soberman RJ (2002). "Membrane localization and topology of leukotriene C4 synthase". J. Biol. Chem. 277 (32): 28902–8. doi:10.1074/jbc.M203074200. PMID 12023288.

== External links == The MEROPS online database for peptidases and their inhibitors: S01.001 Archived 2019-09-15 at the Wayback Machine Chymotrypsin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

Sources: en.wikipedia.org

Notes from published material

Although vultures are the only birds that depend on carrion for food, many other birds eat carrion opportunistically. Numerous birds of prey, for example wedge-tailed eagles, brown goshawks and buzzards, feed on carrion. Long-eared owls and great horned owls also feed on carrion, as do wading birds such as the marabou stork and greater adjutant, seabirds such as the northern giant petrel and ivory gull, and passerine birds such as the carrion crow, rook and forest raven. Types of carrion eaten include dead wildlife, dead livestock, roadkill, and carrion stolen from vultures or raided from crocodile caches.

== Structural studies == As of late 2007, 29 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1A27​, PDB: 1BHS​, PDB: 1DHT​, PDB: 1EQU​, PDB: 1FDS​, PDB: 1FDT​, PDB: 1FDU​, PDB: 1FDV​, PDB: 1FDW​, PDB: 1GZ6​, PDB: 1I5R​, PDB: 1IKT​, PDB: 1IOL​, PDB: 1JTV​, PDB: 1QYV​, PDB: 1QYW​, PDB: 1QYX​, PDB: 1S1P​, PDB: 1S1R​, PDB: 1S2A​, PDB: 1S2C​, PDB: 1XF0​, PDB: 1YB1​, PDB: 1ZQ5​, PDB: 2F38​, PDB: 2FGB​, PDB: 2HQ1​, PDB: 2PD6​, and PDB: 3DHE​.

The Strep-tag system is a method which allows the purification and detection of proteins by affinity chromatography. The Strep-tag II is a synthetic peptide consisting of eight amino acids (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys). This peptide sequence exhibits intrinsic affinity towards Strep-Tactin, a specifically engineered streptavidin, and can be N- or C- terminally fused to recombinant proteins. By exploiting the highly specific interaction, Strep-tagged proteins can be isolated in one step from crude cell lysates. Because the Strep-tag elutes under gentle, physiological conditions, it is especially suited for the generation of functional proteins. Strep-tag, Twin-Strep-tag and Strep-Tactin are registered trademarks of IBA Lifesciences GmbH.

== Intellectual property == A2 Corporation licensed patents filed in the 1990s by the New Zealand Dairy Board and filed its own patents on genetic tests to determine what form of beta-casein cows produce in milk and concerning potential adverse health consequences of standard milk. By 2012 A2 Corporation had developed a worldwide suite of intellectual property, including trademarks, trade secrets, and patents covering products, the genetic test and methods to develop A1 protein-free producing herds, as well as methods to check the protein content and fatty acid content of milk, dietary supplements with A2 beta-casein, and even therapeutic uses of A1 protein-free products. The a2 Milk Company continues to develop a portfolio of intellectual property, including trademarks and patents. The a2 Milk Company also invests in targeted research and development associated with the benefits of the A2 protein. In September 2017, it was reported that the a2 Milk Company got approval to keep selling its products in China.

Sources: en.wikipedia.org

Further detail

Type I – originates in ascending aorta, and propagates at least to the aortic arch and often beyond it distally. It is most often seen in patients less than 65 years of age and is the most lethal form of the disease. Type II – originates in the ascending aorta and is confined to it. Type III – originates in the descending aorta and rarely extends proximally, but will extend distally. It most often occurs in elderly patients with atherosclerosis and hypertension.

A small N-terminal domain (160 amino-acid residues) A large C-terminal domain (240 amino-acid residues) Each noncovalently-associated monomer subunit consists of both domains. The subunits interact with each other through about 20 hydrogen bonds and four ion pairs, providing stability to the dimer. The two domains in each monomer subunit are more loosely connected, with only six hydrogen bonds and one ion pair between them, and no intra- or intermolecular disulfide bonds. Looking more closely at the two domains, the following structures were described in 1988:

=== Mechanisms and therapeutics for neurodevelopmental disorders === Sur’s group has applied this understanding of plasticity to study disorders of brain development. Rett Syndrome is a devastating neurodevelopmental disorder caused by mutations in MECP2, a transcriptional regulator. Sur hypothesized that a core mechanism of Rett Syndrome is the persistence of immature synapses which may be induced to mature. Rett model mice indeed have a deficit in PI3K/Akt/Erk signaling and PSD95 expression, leading to immature excitatory synapses and prolonged visual cortex plasticity that extends into adulthood. Application of IGF1(1-3) peptide, which degrades IGF binding proteins produced by astrocytes and enhances IGF1 availability, and of full-length IGF1, upregulates these signals to restore normal synaptic plasticity and function and improve behavioral phenotypes. Human Rett IPSC-derived neurons show deficits in IGF1 and similar effectiveness of IGF1 in restoring PI3K, AKT and S6 signals. Based on the lab’s work, an IGF1(1-3) mimetic – trofinetide - was employed in clinical trials for Rett Syndrome. In 2023, trofinetide was approved by the FDA as the first treatment for Rett Syndrome. This work has played an important part in raising optimism that even major disorders of brain development may be treated effectively when understood mechanistically.

== See also == Digital mammography: use of a computer to produce images of the breast Global radiology: improving access to radiology resources in poor and developing countries Medical radiography: the use of ionizing electromagnetic radiation, such as X-rays, in medicine Radiation protection: the science of preventing people and the environment from suffering harmful effects from ionizing radiation Radiologists Without Borders Radiosensitivity: measure of the susceptibility of organic tissues to the harmful effects of radiation X-ray image intensifier: equipment that uses X-rays to produce an image feed displayed on a TV screen International Day of Radiology: an awareness day for medical imaging Electrogram

===== ANTHEM-UC ===== The ANTHEM-UC study is a phase IIb trial evaluating icotrokinra in adults with moderately to severely active ulcerative colitis. The study met its primary endpoint of clinical response, with patients treated with the highest dose of icotrokinra achieving a response rate of 63.5% at week 12 versus 27% for placebo.

Sources: en.wikipedia.org

Frequently asked questions

What class of compound is ipamorelin?

It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.

How does ipamorelin differ from ghrelin?

Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.

Is the mechanism of action fully established?

Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.

Is ipamorelin an approved medicine?

It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.

Network